Elihu Estey

[Elihu Estey @ElihuEstey]

@TapKadia @mtmdphd @LeukemiaMDA We are trying to update it.

[Elihu Estey @ElihuEstey]

@TapKadia @mtmdphd @ElihuEstey @LeukemiaMDA

[Elihu Estey @ElihuEstey]

@ElihuEstey test

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi dr daver discussed combo aza w checkpoint inhibs.Low # mutations may make AML cells less antigenic than melanoma

[Elihu Estey @ElihuEstey]

@fredhutch #ALCXVI dr dispersio reviewed issues w CAR in AML inc need to avoid affecting monocytes which mediate cytokine release syndrome

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi much discussion about rx of MRD + AML.EG given risks of SCT & poor results of SCT in MRD+ should these pts receive SCT

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi dr lo coco noted >95% of APL pts w low WBC can be cured w/o need for chemotherapy

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi Dr Dohner discussed trials which in >50% of cases RX is targeted to patients specific molecular profiles. The future!

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi nice talk by Dr Stone: midostaurin added to 7+3 is new standard for adults under age 60 with FLT3+ AML

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi interesting talk by Dr Bejar:discovery of significant clonal heterogeneity can aid diagnosing MDS in equivocal cases

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi nice talk about familial AML predisposition syndromes.It is now essential to ask about family history in AML pets

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi discussion about changes in mutations between MDS & AML & speculation decitabine may affect P53 mutations unlike 7+3

[Elihu Estey @ElihuEstey]

@fredhutch #alcxvi changes Changes in epigenetic profiles occur between Dx & relapse in a pt specific fashion

[Elihu Estey @ElihuEstey]

@realDonaldTrump

[Elihu Estey @ElihuEstey]

#ALCXVI16
Test

[Elihu Estey @ElihuEstey]

@ElihuEstey
Test

[Elihu Estey @ElihuEstey]

5 ##pp5

[Elihu Estey @ElihuEstey]

I. A